"I am very grateful to receive research funding from ARI. Importantly, this funding will directly support the Swedish Glaucoma Nicotinamide Trial with a specific aim of this funding to identify systemic biomarkers of glaucoma/disease progression and the efficacy of nicotinamide treatment. Being recognised internationally for our current work in Sweden is of huge importance to promote vision research in a more global context and to demonstrate the skills and expertise we have here at St. Erik Eye Hospital and Karolinska Institutet," Pete Williams says.